Skip to main content

Table 1 Rates of HIV-1 infections in the vaccinees and in placebo inoculated volunteers enrolled in the STEP vaccine trial.

From: The aftermath of the Merck's HIV vaccine trial

 

No immunity to Ad5 (< 18 units)

Medium

immunity to Ad5

(18–200 units)

High immunity to Ad5

(201–1000 units)

Very high immunity

to Ad5 (> 1000 units)

Vaccinea

20 infected

out of 382 total

8 infected

out of 140 total

14 infected out of

229 total

7 infected out of 163

total

Placebob

20 infected out

of 394 total

4 infected

out of 142 total

7 infected out of 229

total

2 infected out of 157

total

  1. a. Subjects were inoculated with three rAD5 vectors expressing gag, pol or nef coding sequences.
  2. b. Control subjects were inoculated with an inactive substance (saline). Immunity to Ad5 vector was assessed by ELISA titers of the antibody response to the rAd5 vector.